Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.
Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.
复制标题
DOI：
10.1001/jamanetworkopen.2020.20969
复制
发表时间：
2020-10-01
影响因子：
13.8
通讯作者：
Gellad WF
中科院分区：
文献类型：
--
作者：
Luo J;Feldman R;Rothenberger SD;Hernandez I;Gellad WF
这项横断面研究评估了医疗保险D部分计划中常用胰岛素产品的药物覆盖范围、处方集限制、零售价格中位数和年度自付费用。
This cross-sectional study assesses drug coverage, formulary restrictions, median retail prices, and annual out-of-pocket costs associated with commonly used insulin products across Medicare Part D plans.